Amryt Pharma 将来の成長

Future 基準チェック /56

Amryt Pharmaは、53.9%と26.3%でそれぞれ年率53.9%で利益と収益が成長すると予測される一方、EPSはgrowで50.8%年率。

主要情報

53.9%

収益成長率

50.8%

EPS成長率

Pharmaceuticals 収益成長	23.6%
収益成長率	26.3%
将来の株主資本利益率	n/a
アナリストカバレッジ	Low
最終更新日	12 Apr 2023

今後の成長に関する最新情報

Recent updates

Amryt gets EMA panel nod for Mycapssa to retain orphan drug status in EU

Oct 18

Amryt growth hormone disorder drug Mycapssa gets EMA panel nod for EU approval

Sep 16

Amryt gets British marketing approval & orphan drug designation for rare skin disease gel

Sep 08

Amryt stock rises 11% on FDA orphan drug status for Mycapssa for rare tumor condition

Jul 14

Amryt and Medison Pharma inks distribution deal for Juxtapid, Lojuxta and Myalept

Feb 04

Amryt's AP103 an Orphan Drug in U.S. for skin blistering disorder

Dec 23

Amryt Group's Lojuxta receives marketing approval in Brazil

Dec 09

業績と収益の成長予測

NasdaqGS:AMYT - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2025	595	153	N/A	N/A	1
12/31/2024	428	141	N/A	N/A	2
12/31/2023	325	-3	59	N/A	4
12/31/2022	266	-64	34	N/A	4
9/30/2022	244	-1	107	108	N/A
6/30/2022	239	3	-32	-30	N/A
3/31/2022	233	3	4	5	N/A
12/31/2021	223	1	14	16	N/A
9/30/2021	210	-88	-89	-86	N/A
6/30/2021	203	-81	46	50	N/A
3/31/2021	186	-92	21	23	N/A
12/31/2020	183	-105	24	27	N/A
9/30/2020	180	-87	5	6	N/A
6/30/2020	140	-92	-18	-17	N/A
3/31/2020	98	-87	-26	-26	N/A
12/31/2019	58	-63	-38	-37	N/A
12/31/2018	17	-30	-16	-15	N/A

アナリストによる今後の成長予測

収入対貯蓄率: AMYTは今後 3 年間で収益性が向上すると予測されており、これは貯蓄率 ( 2.1% ) よりも高い成長率であると考えられます。

収益対市場: AMYT今後 3 年間で収益性が向上すると予想されており、これは市場平均を上回る成長と考えられます。

高成長収益: AMYT今後 3 年以内に収益を上げることが予想されます。

収益対市場: AMYTの収益 ( 26.3% ) US市場 ( 8.8% ) よりも速いペースで成長すると予測されています。

高い収益成長: AMYTの収益 ( 26.3% ) 20%よりも速いペースで成長すると予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: AMYTの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

Amryt Pharma 将来の成長

Future 基準チェック /56

主要情報

今後の成長に関する最新情報

Amryt Pharma plc Re-Affirms Revenue Guidance for the Year 2022

Amryt Pharma plc Provides Earnings Guidance for the Full Year 2022

Amryt Pharma plc Reaffirms Revenue Guidance for Fiscal Year 2022

Amryt Pharma plc Revises Revenue Guidance for the Year 2021

Amryt Pharma plc Announces Earnings Guidance for the Fiscal Year 2021

Amryt Pharma plc Raises Sales Guidance for the Full Year 2020

Recent updates

Amryt Announces Positive Top Line Results from Phase 3 Pediatric Trial of Lomitapide in HoFH

Amryt Announces European Commission Approves Mycapssa® for the Treatment of Acromegaly

Amryt Pharma plc Re-Affirms Revenue Guidance for the Year 2022

Amryt Pharma plc to Report Q3, 2022 Results on Nov 03, 2022

Amryt Announces COMP Adopts Positive Opinion on Orphan Disease Designation for Mycapssa for Treatment of Acromegaly

Amryt Receives Reimbursement Approval from the Dutch Ministry of Health for Myalepta (Metreleptin)

Amryt gets EMA panel nod for Mycapssa to retain orphan drug status in EU

Amryt growth hormone disorder drug Mycapssa gets EMA panel nod for EU approval

Amryt Receives Marketing Authorisation Approval and Orphan Drug Designation for Filsuvez(R) in Great Britain

Amryt Receives Marketing Authorisation Approval and Orphan Drug Designation for Filsuvez(R) in Great Britain

Amryt gets British marketing approval & orphan drug designation for rare skin disease gel

Amryt Pharma plc Provides Earnings Guidance for the Full Year 2022

Amryt Pharma plc to Report Q2, 2022 Results on Aug 04, 2022

Amryt Receives Orphan Drug Designation from the FDA for Mycapssa(R) (oral octreotide) for the Treatment of Carcinoid Syndrome

Amryt stock rises 11% on FDA orphan drug status for Mycapssa for rare tumor condition

Amryt Announces Appointment of Dr Tracy Cunningham as Chief Medical Officer

Amryt to Pursue Formal Dispute Resolution for Oleogel-S10 (Filsuvez®) NDA

Amryt Announces European Commission Approves Filsuvez® for the treatment of Dystrophic and Junctional EB

Amryt's Filsuvez gets approval in EU to treat rare skin disorder

Amryt Presents Data for Mycapssa (Oral Octreotide) from OPTIMAL and MPOWERED Phase 3 Trials at ENDO 2022

Amryt to Present Data from OPTIMAL and MPOWERED Phase 3 Trials Open Label Extension of Mycapssa(R) (oral octreotide) at ENDO 2022

Amryt Pharma plc, Annual General Meeting, Jun 30, 2022

Amryt Pharma plc Announces New Patent for Mycapssa®

Amryt Pharma plc Reaffirms Revenue Guidance for Fiscal Year 2022

CHMP Adopts positive opinion for Filsuvez(R) for the treatment of Dystrophic and Junctional EB

Amryt Pharma plc to Report Q1, 2022 Results on May 04, 2022

Amryt Announces Positive Long-Term Safety and Efficacy Data for Mycapssa® (oral octreotide) from the 2nd Year of OPTIMAL Open Label Extension Study in Acromegaly Patients

Amryt Announces Successful Bioavailability Study for Mycapssa® (Octreotide Capsules)

Amryt Receives Complete Response Letter from the U.S. Food and Drug Administration for Oleogel-S10 NDA

Amryt Announces Oleogel-S10 EMA Regulatory Update

Amryt Announces Positive Long-Term Safety and Efficacy Data confirming the role for Mycapssa® (oral octreotide)

The Lancet Diabetes & Endocrinology Publishes Positive Results for the MPOWERED Phase 3 Trial for Mycapssa® (oral octreotide) in Acromegaly Patients

Amryt Pharma: Advancing Novel Treatments For Rare And Debilitating Conditions

Amryt Pharma plc Provides Update on Regulatory Review Process for Oleogel-S1

Amryt Announces the Cancellation of Admission of Its Ordinary Shares to Trading on AIM

Amryt Pharma plc Revises Revenue Guidance for the Year 2021

Amryt Pharma plc Announces Earnings Guidance for the Fiscal Year 2021

Amryt Pharma plc completed the acquisition of Chiasma, Inc. from MPM Capital and others.

U.S. Food and Drug Administration Confirms Amryt’s New Drug Application for Oleogel-S10 Will Not Require an Advisory Committee Meeting

U.S. Food and Drug Administration Grants Priority Review for New Drug Application for Oleogel-S10 for the Treatment of Epidermolysis Bullosa

Amryt Pharma plc entered into an agreement to acquire Chiasma, Inc. from MPM Capital and others for approximately $290 million.

Chiasma surges on merger agreement with Amryt

Amryt and Medison Pharma Canada Sign Distribution Agreement for Myalepta (Metreleptin) in Canada

Amryt Pharma plc to Report Q4, 2020 Results on Mar 04, 2021

Amryt and Medison Pharma Sign Multi-Regional Distribution Agreements in Canada and Israel

Amryt and Medison Pharma inks distribution deal for Juxtapid, Lojuxta and Myalept

Amryt Pharma plc Receives Reimbursement Approval from Nice for Myalepta in England and Wales

Amryt's AP103 an Orphan Drug in U.S. for skin blistering disorder

Amryt Receives Ministry of Health Reimbursement Approval for Lojuxta® (Lomitapide) in Saudi Arabia

Amryt Group Receives Marketing Authorisation Approval for Lojuxta in Brazil

Amryt Group's Lojuxta receives marketing approval in Brazil

Amryt Pharma plc Raises Sales Guidance for the Full Year 2020

Amryt Announces Positive Results from Phase 3 Trial of Filsuvez® in Epidermolysis Bullosa

Amryt Signs Distribution Agreement with Swixx BioPharma AG

Amryt and Swixx Sign Distribution Deal for Lojuxta

Amryt Pharma plc to Report Q3, 2020 Results on Nov 05, 2020

Amryt Pharma Intends to Cancel the Admission of the Ordinary Shares to Trading on the Euronext Growth Market

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘